These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 24080651

  • 1. Daptomycin activity against uncommonly isolated streptococcal and other gram-positive species groups.
    Sader HS, Flamm RK, Farrell DJ, Jones RN.
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6378-80. PubMed ID: 24080651
    [Abstract] [Full Text] [Related]

  • 2. Comprehensive update of dalbavancin activity when tested against uncommonly isolated streptococci, Corynebacterium spp., Listeria monocytogenes, and Micrococcus spp. (1357 strains).
    Jones RN, Stilwell MG.
    Diagn Microbiol Infect Dis; 2013 Jun; 76(2):239-40. PubMed ID: 23414746
    [Abstract] [Full Text] [Related]

  • 3. Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis.
    Streit JM, Steenbergen JN, Thorne GM, Alder J, Jones RN.
    J Antimicrob Chemother; 2005 Apr; 55(4):574-8. PubMed ID: 15722390
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of daptomycin against Gram-positive cocci: the first multicentre study in Greece.
    Malli E, Spiliopoulou I, Kolonitsiou F, Klapsa D, Giannitsioti E, Pantelidi K, Pratti A, Panopoulou M, Grapsa S, Alepopoulou E, Neonakis I, Frantzidou F, Alexiou-Daniel S, Bakola D, Koutsia-Carouzou C, Malamou-Lada H, Zerva L, Vlahaki E, Kartali-Ktenidou S, Anastassiou ED, Petinaki E.
    Int J Antimicrob Agents; 2008 Dec; 32(6):525-8. PubMed ID: 18774268
    [Abstract] [Full Text] [Related]

  • 5. In vitro activity of LY146032 (daptomycin), a new peptolide.
    Ehlert F, Neu HC.
    Eur J Clin Microbiol; 1987 Feb; 6(1):84-90. PubMed ID: 3032611
    [Abstract] [Full Text] [Related]

  • 6. Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide.
    Mendes RE, Sader HS, Flamm RK, Jones RN.
    J Antimicrob Chemother; 2014 Jun; 69(6):1579-81. PubMed ID: 24505091
    [Abstract] [Full Text] [Related]

  • 7. Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group Streptococci after exposure to daptomycin.
    García-de-la-Mària C, Pericas JM, Del Río A, Castañeda X, Vila-Farrés X, Armero Y, Espinal PA, Cervera C, Soy D, Falces C, Ninot S, Almela M, Mestres CA, Gatell JM, Vila J, Moreno A, Marco F, Miró JM, Hospital Clinic Experimental Endocarditis Study Group.
    Antimicrob Agents Chemother; 2013 May; 57(5):2319-25. PubMed ID: 23478959
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
    Biedenbach DJ, Arhin FF, Moeck G, Lynch TF, Sahm DF.
    Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of dalbavancin and five comparator agents against common and uncommon Gram-positive organisms isolated from cancer patients.
    Rolston KV, Wang W, Nesher L, Shelburne SA, Prince RA.
    J Antibiot (Tokyo); 2016 May; 69(5):381-7. PubMed ID: 26626876
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria.
    Jorgensen JH, Maher LA, Redding JS.
    Eur J Clin Microbiol; 1987 Feb; 6(1):91-6. PubMed ID: 3032612
    [Abstract] [Full Text] [Related]

  • 11. In vitro activity of the new glycopeptide decaplanin.
    Neu HC, Chin NX, Niu WW.
    Eur J Clin Microbiol Infect Dis; 1992 May; 11(5):458-62. PubMed ID: 1330562
    [Abstract] [Full Text] [Related]

  • 12. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
    Pfaller MA, Mendes RE, Sader HS, Castanheira M, Flamm RK.
    J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. In vitro activity of SCH-34343, a new penam, and other antimicrobial agents against clinical isolates from cancer patients.
    Rolston KV, Alvarez ME, Hoy JF, Alderman HC, Ho DH, Bodey GP.
    Chemotherapy; 1986 Dec; 32(6):506-14. PubMed ID: 3100147
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017.
    Morrissey I, Hawser S, Lob SH, Karlowsky JA, Bassetti M, Corey GR, Olesky M, Newman J, Fyfe C.
    Antimicrob Agents Chemother; 2020 Feb 21; 64(3):. PubMed ID: 31843997
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. In-vitro activity of LY146032 against Staphylococcus aureus, Listeria monocytogenes, Corynebacterium JK, and Bacillus spp., in comparison with various antibiotics.
    Van der Auwera P, Grenier P, Klastersky J.
    J Antimicrob Chemother; 1987 Aug 21; 20(2):209-12. PubMed ID: 2822648
    [Abstract] [Full Text] [Related]

  • 20. In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013).
    Huband MD, Castanheira M, Farrell DJ, Flamm RK, Jones RN, Sader HS, Mendes RE.
    Int J Antimicrob Agents; 2016 Jun 21; 47(6):495-9. PubMed ID: 27211209
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.